United States Últimas notícias

Bank of Japan officials are reportedly open to raising interest rates at a faster pace than the consensus among economists, with no pre-set course in mind, as the yen's continued weakness adds to upside inflation risks. Morwenna Coniam reports on Bloomberg Television.

Cal-Maine Foods (NASDAQ:CALM) reported $552.6 million in fourth-quarter sales and a $35.9 million loss, or $0.76 per share.

Repligen (NASDAQ:RGEN) agreed to acquire BioLife Solutions (NASDAQ:BLFS) in a cash-and-stock transaction valued at approximately $1.5 billion.

Joby Aviation (NYSE:JOBY) signed a multi-year agreement making Virgin Atlantic its exclusive UK airline partner for air taxi services.

Schroders Group CIO Johanna Kyrklund discusses the artificial intelligence trade and why she sees value in quality. "Why are those quality stocks cheap is in many cases they've been caught up with this AI disruption story," Kyrklund says on Bloomberg Television. "It's the other side of the AI trade."

EU regulators will formally outline subsidy concerns against JD.com (NASDAQ:JD) over its $2.5 billion bid for Ceconomy.

ChatGPT-maker OpenAI said its advanced artificial intelligence models inadvertently hacked Hugging Face Inc. in an "unprecedented" incident that prompted fresh calls for curbs on the technology. Bloomberg Intelligence's Matt Bloxham has the details.

Alphabet (NASDAQ:GOOG) reported second-quarter revenue of $119.8 billion, up 24%, as Services and Cloud sales increased.

ServiceNow (NYSE:NOW) reported second-quarter subscription revenue of $3.88 billion, up 24.5%, as total revenue increased 24% to $3.99 billion.

Anna Edwards, Guy Johnson, Tom Mackenzie and Adam Linton break down today's key themes for analysts and investors on "Bloomberg: The Opening Trade."

Genenta (NASDAQ:GNTA) said Sòphia High Tech’s FY2025 sales rose 29.3% to €7.17 million, alongside increased operating profitability.

Generic drug manufacturers will have two years to move production to the US or face a 100% import duty from August 2028, President Donald Trump said, threatening the supply of low-cost medicines that millions of Americans rely on. Bloomberg's Deirdre Hipwell reports.